Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 25;13(1):4899.
doi: 10.1038/s41598-023-31700-x.

Lymphocyte to monocyte ratio predicts survival and is epigenetically linked to miR-222-3p and miR-26b-5p in diffuse large B cell lymphoma

Ayman Mohamed Metwally  1 , Ameera Abdel Hamed Mahmoud Kasem  2 , Magda Ismail Youssif  2 , Safia Mohammed Hassan  2 , Abdel Hady A Abdel Wahab  3 , Lobna Ahmed Refaat  4
Affiliations

Lymphocyte to monocyte ratio predicts survival and is epigenetically linked to miR-222-3p and miR-26b-5p in diffuse large B cell lymphoma

Ayman Mohamed Metwally et al. Sci Rep. .

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. 10-20% of the patients present with bone marrow (BM) involvement which predicts a worse survival. This study aimed to determine the prognostic significance of serum miR-222-3p, miR-26b-5p, EBV-miR-BHRF1-2-5p, and EBV-miR-BHRF1-2-3p and correlate their levels to clinical and haematological markers in DLBCL with special emphasis on the lymphocyte-monocyte ratio (LMR) and neutrophil-monocyte ratio. We also studied the role of BM BMI1 and PIM2 proteins in predicting BM infiltration. Serum miRNAs were studied on 40 DLBCL and 18 normal individuals using qRT-PCR. BMI1 and PIM2 proteins were studied on BM biopsies by immunohistochemistry. The results were correlated with clinical and follow-up data. All the studied miRNAs were dysregulated in DLBCL serum samples. BMI1 and PIM2 were expressed in 67% and 77.5% of BM samples, respectively. LMR was significantly associated with disease-free survival (DFS) (P = 0.022), miR-222-3P (P = 0.043), and miR-26b-5p (P = 0.043). EBV-miR-BHRF1-2-3p was significantly correlated to haemoglobin level (P = 0.027). MiR-222-3p, miR-26b-5p, and EBV-miR-BHRF1-2-5p expressions were significantly correlated to each other (P = 0.001). There was no significant correlation between the studied markers and follow-up data. LMR is a simple method for predicting survival in DLBCL. MiR-222-3p and miR-26b-5p may be implicated in an immunological mechanism affecting patients' immunity and accordingly influence LMR. The correlation between miR-222-3p, miR-26b-5p, and EBV-miR-BHRF1-2-5p may indicate a common mechanism among the 3 miRNAs that may explain DLBCL pathogenesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
(a) Kaplan–Meier curve for OS with BM infiltration. Overall Survival (OS), Bone Marrow infiltration (B M infiltration). (b) Kaplan–Meier curve for OS and platelets count. Overall Survival (OS).
Figure 2
Figure 2
Kaplan–Meier curve for DFS with L/M ratio. Disease Free Survival (DFS), Lymphocyte/Monocyte ratio (L/M ratio).
Figure 3
Figure 3
(a) Kaplan–Meier curve for PFS with splenomegaly. Progression Free Survival (PFS). (b) Kaplan–Meier curve for PFS with hemoglobin level. Progression Free Survival (PFS).
See this image and copyright information in PMC

References

    1. Swerdlow S, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon. IARC; 2008.
    1. Zerbini M, Soares F, Velloso E, Chaufaille M, Paes R. World Health Organization Classification of tumors of hematopoietic and lymphoid tissues, 4th edition; 2008 – major changes from the 3rd edition. Rev. Assoc. Med. Bras. 2001;57(1):66–73. doi: 10.1016/S0104-4230(11)70019-7. - DOI
    1. Soliman A, Boffetta P. Lymphoma and leukemia. In: Freedman LS, Edward BK, Ries LA, Young JL, editors. Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. National Cancer Institute; 2006.
    1. Flowers C, Sinha R, Vose J. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J. Clin. 2010;60(6):393–408. - PubMed
    1. Staudt L. Gene expression profiling of lymphoid malignancies. Annu. Rev. Med. 2002;53:303–318. doi: 10.1146/annurev.med.53.082901.103941. - DOI - PubMed